You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
寶萊特(300246.SZ):子公司獲得血液透析濃縮液的醫療器械註冊證
格隆匯 11-22 20:18

格隆匯11月22日丨寶萊特(300246.SZ)公佈,公司控股子公司武漢柯瑞迪醫療用品有限公司(“武漢柯瑞迪”)於近日獲得國家藥品監督管理局(“國家藥監局”)頒發的《醫療器械註冊證》。

此次武漢柯瑞迪獲得的血液透析濃縮液的醫療器械註冊證,為目前湖北省內唯一的主流配方透析液產品註冊證。此次獲證的新產品對比武漢柯瑞迪原有的血液透析濃縮液產品,能夠更好地滿足大部分血透患者的臨牀使用需求,將有效地補全武漢柯瑞迪的產品鏈,提升武漢柯瑞迪產品的市場競爭力,並進一步豐富了公司產品類別。

目前,公司擁有天津摯信鴻達、遼寧恆信生物、常州華嶽、武漢柯瑞迪、南昌寶萊特及珠海園區共六大血液透析粉/液生產基地,涵蓋了全國包括東北、華北、華東、華中、華南地區,此外,四川寶萊特透析粉液生產基地已建成,目前處於待產狀態,預計明年內投產。數年來,公司生產的血液透析粉/液已覆蓋國內多數醫院及血液透析中心,實現了國內市場份額領先。未來,公司將充分把握產品技術優勢,為國內血液淨化行業提供更多優質產品,同時更大程度地結合公司營銷網絡佈局,發揮協同效應,更快地推動公司在血液淨化領域上戰略目標的實現。

上述產品上市後實際銷售情況取決於未來市場的推廣效果,公司目前尚無法準確預測上述產品對公司未來營業收入的影響,敬請投資者給予關注並注意投資風險。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account